Bristol-Myers Squibb & Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) announced today that the FDA has approved an additional indication of Bristol’s anti-blood clot medicine, Eliquis. Pfizer Inc. (NYSE:PFE) stock performance was 0.35% in last session and finished the day at $31.23. Traded volume was 27.11 million shares in the last session and the average volume of the stock remained 27.87 million shares. The beta of the stock remained 0.67. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.

Cambridge drug developer Idenix Pharmaceuticals Inc. has filed lawsuits in Europe charging that biotechnology giant Gilead Sciences Inc. (NASDAQ:GILD) infringed on an Idenix patent when it marketed a popular new hepatitis C treatment in England, France, and Germany. Gilead Sciences, Inc. (NASDAQ:GILD) dropped -3.79% to $75.05 yesterday on volume of 18.78 million shares. The intra-day range of the stock was $74.55 – $77.10. Gilead Sciences, Inc. (NASDAQ:GILD) has a market capitalization of 115.12 billion.

Investors in Celgene Corp. (NASDAQ:CELG) got a couple of scares Friday when the biotech company’s shares plunged in early trading over concerns that British regulators don’t want to approve use of its Revlimid medication in certain uses and the prospect of an early patent expiration on that same drug. Celgene Corporation (NASDAQ:CELG)’s stock on March 14, 2014 reported a lower of -4.22% to the closing price of $149.41. Its fifty two weeks range is $108.01 – $174.66. The total market capitalization recorded 61.42 billion. The overall volume in the last trading session was 8.40 million shares. In its share capital, Celgene Corporation (NASDAQ:CELG) has 411.10 million outstanding shares.

Ariad Pharmaceuticals (NASDAQ:ARIA) was the target of a large decrease in short interest in the month of January. As of February 14th, there was short interest totaling 42,140,907 shares, a decrease of 2.7% from the January 31st total of 43,302,340 shares, Stock Ratings Network reports. Approximately 23.4% of the shares of the company are sold short. Based on an average trading volume of 21,063,414 shares, the short-interest ratio is presently 2.0 days. On Friday, shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) advanced 8.79% to close the day at $8.17. Company return on investment (ROI) is -220.70% and its monthly performance is recorded as -1.92%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) quarterly revenue growth is 100.74%.